The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Reversal of Hepatic Fibrosis — Fact or Fantasy?
Abstract
The prospect of reversing hepatic fibrosis has generated great interest now that basic science advances are being translated into promising new antifibrotic therapies. It is appropriate to recognize both the historical advances that created the framework for these successes, and the important role that Hepatology has played in disseminating them. A sense of urgency underlies this effort as the epidemics of HCV and NASH are becoming associated with advancing fibrosis. To maintain progress and minimize confusion among investigators and clinicians it is essential to standardize terms referring to fibrosis ‘reversal’ and ‘regression.’ There must also be rapid optimization of non-invasive markers of fibrosis to relieve this current bottleneck to conducting clinical trials. Progress in identifying genetic determinants of fibrosis could further refine patient selection for clinical trials and shorten their duration, as well as unearthing new directions of scientific inquiry. Realistic expectations for successful anti-fibrotic therapies reflect solid evidence of fibrosis regression in patients treated effectively for viral liver disease, as well as growing clarity in the understanding mechanisms of extracellular matrix production and degradation. The paradigms of stellate cell activation and apoptosis remain valuable frameworks for understanding pathways of hepatic fibrogenesis and fibrosis regression, respectively. Continued progress is essential in order to identify the determinants and dynamics of fibrosis reversibility, to discover additional targets for anti-fibrotic therapy, and to develop customized multi-drug regimens. These advances are sure to be captured in the next 25 years by Hepatology, and to profoundly impact the prognosis of patients with chronic liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Knodell, R. G., Ishak, K. G., Black, W. C., Chen, T. S., Craig, R., Kaplowitz, N., Kiernan, T. W., & Wollman, J. (1981) · Hepatology · doi:10.1002/hep.1840010511 · Cited by 3,522
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
Classification of chronic hepatitis: Diagnosis, grading and staging
Desmet, V. J., Gerber, M., Hoofnagle, J. H., Manns, M., & Scheuer, P. J. (1994) · Hepatology · doi:10.1002/hep.1840190629 · Cited by 2,593
Sampling Variability of Liver Fibrosis in Chronic Hepatitis C
Bedossa, P., Dargère, D., & Paradis, V. (2003) · Hepatology · doi:10.1016/j.hep.2003.09.022 · Cited by 2,376
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection
Regev, A., Berho, M. E., Jeffers, L. J., Milikowski, C., Molina, E. G., Pyrsopoulos, N., Feng, Z.-Z., Reddy, K. R., & Schiff, E. R. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04396-4 · Cited by 2,093
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649
Bataller, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524282c1 · Cited by 1,472
Cited by
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Self-citationPathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Self-citationAssessment of Hepatic Fibrosis With Magnetic Resonance Elastography
Yin, M., Talwalkar, J. A., Glaser, K. J., Manduca, A., Grimm, R. C., Rossman, P. J., Fidler, J. L., & Ehman, R. L. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.06.012 · Cited by 948
The pancreatic stellate cell: a star on the rise in pancreatic diseases
Omary, M. B., Lugea, A., Lowe, A. W., & Pandol, S. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30082 · Cited by 692
Magnetic resonance elastography of liver: Technique, analysis, and clinical applications
Venkatesh, S. K., Yin, M., & Ehman, R. L. (2013) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.23731 · Cited by 659
A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response
Ding, N., Yu, R. T., Subramaniam, N., Sherman, M. H., Wilson, C., Rao, R., Leblanc, M., Coulter, S., He, M., Scott, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.028 · Cited by 622
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625
Evolving therapies for liver fibrosis
Schuppan, D., & Kim, Y. O. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66028 · Cited by 595
Evolving challenges in hepatic fibrosis
Friedman, S. L. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.97 · Cited by 581
Self-citationLoomba, R., Lawitz, E., Mantry, P. S., Jayakumar, S., Caldwell, S. H., Arnold, H., Diehl, A. M., Djedjos, C. S., Han, L., Myers, R. P., et al. (2018) · Hepatology · doi:10.1002/hep.29514 · Cited by 549
Garcia‐Tsao, G., Friedman, S., Iredale, J., & Pinzani, M. (2010) · Hepatology · doi:10.1002/hep.23478 · Cited by 538
Self-citationKisseleva, T., & Brenner, D. A. (2008) · Experimental Biology and Medicine · doi:10.3181/0707-mr-190 · Cited by 503
Henegar, C., Tordjman, J., Achard, V., Lacasa, D., Cremer, I., Guerre-Millo, M., Poitou, C., Basdevant, A., Stich, V., Viguerie, N., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-1-r14 · Cited by 471
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future
Friedman, S. L., & Pinzani, M. (2022) · Hepatology · doi:10.1002/hep.32285 · Cited by 430
Self-citationShaheen, A. A. M., Wan, A. F., & Myers, R. P. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01466.x · Cited by 360
Friedman, S. L. (2008) · Toxicology · doi:10.1016/j.tox.2008.06.013 · Cited by 350
Self-citationHepatic inflammation and progressive liver fibrosis in chronic liver disease
Czaja, A. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2515 · Cited by 342
Magnetic resonance imaging of hepatic fibrosis: Emerging clinical applications
Talwalkar, J. A., Yin, M., Fidler, J. L., Sanderson, S. O., Kamath, P. S., & Ehman, R. L. (2008) · Hepatology · doi:10.1002/hep.21972 · Cited by 314
Brief Communication: The Relationship of Regression of Cirrhosis to Outcome in Chronic Hepatitis C
Mallet, V., Gilgenkrantz, H., Serpaggi, J., Verkarre, V., Vallet-Pichard, A., Fontaine, H., & Pol, S. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-6-200809160-00006 · Cited by 299
Targeting Liver Fibrosis: Strategies for Development and Validation of Antifibrotic Therapies†
Popov, Y., & Schuppan, D. (2009) · Hepatology · doi:10.1002/hep.23123 · Cited by 296
The Precarious State of the Liver After a Fontan Operation: Summary of a Multidisciplinary Symposium
Rychik, J., Veldtman, G., Rand, E., Russo, P., Rome, J. J., Krok, K., Goldberg, D. J., Cahill, A. M., & Wells, R. G. (2012) · Pediatric Cardiology · doi:10.1007/s00246-012-0315-7 · Cited by 290
Hepatic stellate cells and the reversal of fibrosis
Kisseleva, T., & Brenner, D. A. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04584.x · Cited by 278
Jeong, W.-I., Park, O., Radaeva, S., & Gao, B. (2006) · Hepatology · doi:10.1002/hep.21419 · Cited by 275
Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases
Gressner, O. A., & Gressner, A. M. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01826.x · Cited by 270
Collagen‐Targeted MRI Contrast Agent for Molecular Imaging of Fibrosis
Caravan, P., Das, B., Dumas, S., Epstein, F. H., Helm, P. A., Jacques, V., Koerner, S., Kolodziej, A., Shen, L., Sun, W., et al. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700700 · Cited by 268
Pearlman, B. L., & Traub, N. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir076 · Cited by 261
Bosch, J., Groszmann, R. J., & Shah, V. H. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.003 · Cited by 252
Patsenker, E., Popov, Y., Stickel, F., Schneider, V., Ledermann, M., Sägesser, H., Niedobitek, G., Goodman, S. L., & Schuppan, D. (2009) · Hepatology · doi:10.1002/hep.23144 · Cited by 174
Drug targeting to the diseased liver
Poelstra, K., Prakash, J., & Beljaars, L. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.02.011 · Cited by 172
Topical tacrolimus for the treatment of secondary lymphedema
Gardenier, J. C., Kataru, R. P., Hespe, G. E., Savetsky, I. L., Torrisi, J. S., Nores, G. D. G., Jowhar, D. K., Nitti, M. D., Schofield, R. C., Carlow, D. C., et al. (2017) · Nature Communications · doi:10.1038/ncomms14345 · Cited by 137
Popov, Y., Sverdlov, D. Y., Bhaskar, K. R., Sharma, A. K., Millonig, G., Patsenker, E., Krahenbuhl, S., Krahenbuhl, L., & Schuppan, D. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00394.2009 · Cited by 136
Radaeva, S., Wang, L., Radaev, S., Jeong, W.-I., Park, O., & Gao, B. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00212.2007 · Cited by 123
Vitamin D and liver fibrosis: molecular mechanisms and clinical studies
Udomsinprasert, W., & Jittikoon, J. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.140 · Cited by 99
Hepatic Stellate Cells and Liver Fibrosis
Puche, J. E., Saiman, Y., & Friedman, S. L. (2013) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2013.tb00529.x · Cited by 89
Self-citationRecent studies of genetic dysfunction in pelvic organ prolapse: The role of collagen defects
Lim, V. F., Khoo, J. K., Wong, V., & Moore, K. H. (2014) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12169 · Cited by 44
Metadata
- Authors
- Friedman, S. L., & Bansal, M. B.
- Venue
- Hepatology
- Published
- 2006-02
- Volume
- 43
- Issue
- Supplement 1
- Pages
- S82-S88
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2038774859
- Cited by
- 379
- References
- 69
- FWCI
- 20.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.